Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K/mTOR pathway, epigenetic regulators, and telomere biology.
平滑肌肉瘤（LMS）是一种起源于平滑肌细胞的侵袭性软组织肉瘤亚型，最常见于子宫和腹膜后。LMS是一种异质性疾病，其临床和分子特征多样，目前尚未被完全阐明。分子谱分析已揭示出若干潜在的治疗靶点，但这些发现尚未转化为LMS获批的靶向疗法。本综述将探讨分子谱分析的历史与最新发现，重点介绍当前研究中具有前景的方向，并提出未来可能推动LMS迈向分子匹配治疗目标的策略。我们将重点关注靶向DNA损伤反应、富含巨噬细胞的微环境、PI3K/mTOR通路、表观遗传调控因子以及端粒生物学等方向。
肿瘤(癌症)患者之家